

# **DRAFT PROGAM**

## **Medical Technology, Biotechnology & Pharmaceuticals**

**Led By:**



**Ms. Sue MacLeman**



**& Dr. Charles Day**

**Wednesday 23<sup>rd</sup> – Tuesday 29<sup>th</sup> May 2018**

## **WEDNESDAY 23<sup>rd</sup> MAY**

**09:00 – 10:30**

**Opening Briefing @ Hotel**

**11:00 – 12:00**

**Start-Up Nation Briefing - Pitango Ventures**

**Mr. Chemi Peres, Managing Partner**

[www.pitango.com](http://www.pitango.com)

Pitango is one of Israel's leading venture capital firms that has been investing in technology entrepreneurs since 1993. With offices in Israel and Silicon Valley, California, Pitango currently manages several venture funds totaling over \$1.6 Billion in committed capital. It is invested in more than 150 companies; among them are companies that have gone public, such as JinkoSolar, RADWARE, Retalix, CardGuard and others as well as companies that were acquired, such as dbMotion (acquired by AllScripts), superDimension (acquired by Covidien), Anobit (acquired by Apple), VideoSuf (acquired by MSFT), and more. Pitango invests in early stage start-ups, as well as growth phase companies in the IT, Life Sciences and Cleantech industries.

Chemi Peres is a Managing General Partner and Co-Founder of Pitango. In 1992, he founded the Mofet Israel Technology Fund, an Israeli venture capital fund publicly traded on the Tel Aviv Stock Exchange. Chemi served as a pilot in the Israeli Air Force for 10 years. Chemi has served on the boards of several NASDAQ companies, such as AudioCodes, BackWeb, Magic Software Enterprises, Aladdin, VocalTec, Orkit Communications and Koor Industries, among others. He currently serves on the boards of numerous Pitango portfolio companies. Chemi also serves as a board member in several non-for-profit organizations. He is chairman of the Peres center for Peace, board member at Social Finance Israel and serves on the board of Governors of The Jewish Diaspora Museum. He holds BSc. degree in Industrial Engineering and MBA from Tel Aviv University.

**12:30 – 13:30**

**Orbimed (includes lunch)**

**Ms. Anat Naschitz, Managing Director**

[www.orbimed.com](http://www.orbimed.com)

OrbiMed is a dedicated healthcare investment firm with investments ranging from biopharmaceuticals to medical devices, diagnostics, and healthcare services. The healthcare industry's powerful growth profile coupled with its magnitude and complexity creates myriad investment opportunities at many different nodes of the healthcare delivery system. The firm invests across the global healthcare industry, from seed-stage venture capital to large, publicly traded companies. Investments are made through one of three strategies: public equity, private equity, or royalty opportunities.

## **WEDNESDAY 23<sup>rd</sup> MAY – CONT'D**

**14:00 – 15:00**

**ElMindA**

**Mr. Ronen Gadot, CEO**

[www.elminda.com](http://www.elminda.com)

ElMindA developed the Brain Networks Activation (BNA) platform, which provides high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain. The platform captures information on the composition, connectivity, synchronization, and operation of brain networks. BNA measurement of the brain's state and changes could potentially be applied to a wide spectrum of indications and their therapeutic interventions, including Alzheimer's disease, Parkinson's disease, concussion, ADHD, pain, stroke, depression, and other conditions related to the central nervous system. The technology also serves in the development of CNS-related treatments.

ElMindA's BNA technology is based on noninvasive recordings of multichannel, EEG-event-related potentials and a comprehensive, multidimensional analysis of those recordings via algorithms.

**15:30 – 16:30**

**ReWalk**

[www.rewalk.com](http://www.rewalk.com)

(ReWalk RWLK:NASADAQ is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs\*. The system allows independent, controlled walking while mimicking the natural gait pattern of the legs. ReWalk offers two systems – ReWalk Personal 6.0 for individuals to use at home in the community, and ReWalk Rehabilitation for use at ReWalk Advanced Training Clinics.)

**19:00**

**Dinner @ Mama's with Guests**

## **THURSDAY 24<sup>th</sup> MAY**

**09:00 – 11:00**

### **TAU**

**Dr. Neta Erez** Department of Pathology, Sackler School of Medicine.

**Dr. Carmit Levy – Carmit Levy Laboratories**

[www.netaerez.tau.ac.il](http://www.netaerez.tau.ac.il)

[www.carmitlevylab.com](http://www.carmitlevylab.com)

**Dr. Erez** and her team used mouse models to study and follow the spontaneous metastasis of melanoma in the brain. Their study revealed early warning signal for brain micrometastases before they become malignant growths. According to the research, micro-tumor cells hijack astrogliosis, the brain's natural response to damage or injury, to support metastatic growth. This knowledge may lead to the detection of brain cancer in its first stages and permit early intervention. Dr. Erez is currently studying detailed molecular pathways in the brain's biological response to find a way to block the metastases, effectively preventing them instead of treating them.

**Carmit Levy Laboratories** are studying the role of microRNAs in development, differentiation and malignant transformation of melanocyte (melanoma). Their studies are focused on melanocytes, with the goal to develop novel approaches in the prevention, diagnosis, and treatment of skin cancer in general and melanoma in particular. In addition, they are using these systems as a model for exploring basic microRNA biogenesis.

**11:30 – 12:30**

### **BrainStorm**

**Mr. Chaim Lebovits, President & CEO**

[www.brainstorm-cell.com](http://www.brainstorm-cell.com)

BrainStorm Cell Therapeutics Inc is a biotechnology company developing autologous stem cell therapies for neurodegenerative disorders such as amyotrophic lateral sclerosis (also known as Lou Gehrig's disease), multiple sclerosis, and Parkinson's disease. NurOwn is BrainStorm's proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells into neurotrophic factor-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site.

## **THURSDAY 24<sup>th</sup> MAY CONT'D**

**13:00 – 16:00**

### **How IoT is Impacting Medicine/Healthcare**

#### **Datos Health**

**Prof. Gabi Bin nun, Co-Founder**

[www.datos-health.com](http://www.datos-health.com)

The Datos platform helps healthcare organizations improve remote patient care by making sense of, and more efficiently managing, the limitless amount of data produced from wearables and personal medical devices. Combining automated management processes with in-depth patient insights and expert clinical predictions, healthcare providers can better manage higher patient volumes at a fraction of the cost. At the physician level, remote digital patient insights are quickly integrated into everyday clinical workflow to enhance decision-making and patient treatment. A patient portal and mobile access for any device empower patients to more easily and successfully manage their health.

#### **LifeMap Sciences**

**Mr. Yaron Guan-Golan, CEO**

[www.lifemapsc.com](http://www.lifemapsc.com)

LifeMap Sciences develops and commercializes next-generation sequencing (NGS) analysis solutions. The company's core technology, the GeneCards Suite Knowledgebase, provides a tool to improve biomedical research and health care. The GeneCards Suite Knowledgebase integrates information from over 120 sources and enables researchers to effectively navigate the universe of human genes, genetic variants, proteins, cells, biological pathways, diseases, and the relationships between them. The GeneCards Suite Knowledgebase also powers the Translational Genomics Expert (TGex), an end-to-end analysis solution for NGS data that provides streamlined interpretation and reporting. TGex empowers NGS analysis by highlighting associations between genes and phenotypes, providing supporting evidence for immediate evaluation, and automatically generating case reports. LifeMap is a subsidiary of BioTime, Inc, and has a subsidiary, LifeMap Solutions, offering solutions for mobile health.

#### **Rethink Pharmaceuticals**

**Dr. Etty Tamir, Co-Founder & CEO**

[www.rethinkpharmaceuticals.com](http://www.rethinkpharmaceuticals.com)

ReThink Pharmaceuticals focuses on finding new uses for existing drugs. The company uses a proprietary algorithm based on evolutionary genomics (phylogenetic profiling) and innovative bioinformatics to find candidates for repurposing. ReThink's algorithm helps researchers discover new gene-disease-drug interactions. As a result, the company can potentially offer a faster, broader, more accurate approach to finding additional new targets for a drug by inferring interactions between the known targets of a therapeutic agent to additional genes associated with other diseases. ReThink investigates potential new indications for drugs already on the market, medications that are under clinical development, and even drugs that failed clinical trials for efficacy reasons. The company's approach goes beyond the boundaries of published data to explore the spectrum of connections between drugs and diseases.

**18:00**

**Dinner**

**20:00**

**Cultural Event**

## **FRIDAY 25<sup>th</sup> MAY**

**09:00 – 10:00**

### **Peregrine Ventures**

**Mr. Boaz Lifschitz, Founding General Partner**

[www.peregrinevc.com](http://www.peregrinevc.com)

Peregrine Ventures is an Israeli venture capital fund investing in promising early-stage high-tech companies with a strong emphasis on life sciences, digital health, and information technology. Working closely with entrepreneurs, Peregrine Ventures and its technological incubator, Incentive, has earned a solid reputation for transforming innovative technologies into lucrative companies with significant global presence.

**11:00 – 13:30**

### **Yad Va'shem Holocaust Memorial**

[www.yadvashem.org](http://www.yadvashem.org)

Yad Va'Shem safeguards the memory of the past and imparts its meaning for future generations. Established in 1953, as the world centre for documentation, research, education and commemoration of the Holocaust, Yad Va'Shem today is a dynamic and vital place of intergenerational and international encounter. For over half a century, Yad Va'Shem has been committed to four pillars of remembrance: Commemoration, Documentation, Research & Education.

@ Har Hazikaron, Jerusalem

*12:30*

*Depart Yad Va'Shem for the Old City*

**14:00 – 17:30**

### **Tour Old City of Jerusalem (includes lunch)**

Jerusalem is considered by many people to be the most holy city in the world. A long, rich history is connected to this city where events central to the traditions of each of the three monotheistic faiths—Judaism, Christianity, and Islam—are believed to have taken place. To the Jewish people it is home to the Western Wall which is considered the holiest Jewish site on account of its proximity to the destroyed two ancient Temples, to the Christians it is where the crucifixion and the resurrection of Jesus took place, and to the Muslims it is where the prophet Muhammad ascended to heaven.

*17:30*

*Depart the Old City for Hotel*

**17:30 – 19:30**

**Free time**

**19:30**

**Traditional Jewish Sabbath Dinner with Guests**

## **SATURDAY 26<sup>th</sup> JUNE**

08:30

*Depart Hotel for Tourism*

**Morning**

### **Mt. Scopus Commonwealth War Graves**

#### **Panoramic View of Jerusalem (Includes wreath laying)**

The ANZACs fought here in both World Wars. In 1917, during World War I, General Allenby's force had been entrenched in front of a strong Turkish position along the Gaza- Beersheba road. On 31 October, an attack on Beersheba was carried out by the 20<sup>th</sup> Corps on the west, and the Desert Mounted Corps on the east. That evening the 4th Australian Light Horse Brigade charged over the Turkish trenches into the town. Although 31 Australians and at least 70 horses were killed in the charge, over 1,000 Turkish soldiers were captured along with large quantities of supplies and ammunition. Popularly recalled as 'one of the last cavalry charges in history', the capture of Beersheba turned the flank of the Turkish defensive line and opened the way for the start of the Palestine campaign which resulted in allied victory in the Middle East in 1918.

### **Masada**

Most famous for the Stand of the Zealots over 2,000 years ago, Masada is located on top of a mountain with breath-taking views. The leaders of the Great Revolt against the Romans occupied Masada after the destruction of the Temple in Jerusalem (70 CE) and withstood the Roman siege. However, after a long struggle, the zealots chose death over slavery.

**Afternoon**

### **The Dead Sea (includes lunch)**

The Dead Sea, located at the lowest point on earth, is a one-of-a-kind body of water and is the saltiest and most mineral-laden in the world. It has its own unique micro-climate with an average of 330 full days of sunshine per year.

16:30

**Return to Hotel**

18:00 – 20:00

### **Dinner with Geopolitical Briefing**

#### **Mr. Jonathan Spyer, Author**

[www.jonathanspyer.com](http://www.jonathanspyer.com)

Jonathan Spyer is a Middle East analyst, author and journalist specializing in the areas of Israel, Lebanon, Syria and broader issues of regional strategy. He is a Senior Research Fellow at the Global Research in International Affairs (GLORIA) Center, and a Fellow at the Middle East Forum.

@ Ambassadors Garden, King David Hotel

20:00

*Depart Hotel for the Old City*

21:10

### **Western Wall Tunnel Tours**

[www.english.thekotel.org](http://www.english.thekotel.org)

The Western Wall Tunnels, a 'time tunnel' to ancient Jerusalem, feature construction, sites, and artifacts that shed light on life in this special city during its most glamorous era, the Second Temple period.

A tour of the Tunnels unveils hidden sections of the Western Wall. It moves through underground passages, mikves and ancient water trenches, streets from the Second Temple era, a quarry used to excavate stones for the Kotel and more. The Western Wall's enormous courses of stone are revealed in full size and magnitude, telling us about the architecture and building practices of different historical eras.

## **SUNDAY 27<sup>th</sup> MAY**

**09:00 – 10:00**

### **BioJerusalem**

**Dr. Shai Melcer, Executive Director**

[www.biojerusalem.org.il](http://www.biojerusalem.org.il)

BioJerusalem is a one-stop connection for those who have made the science of life their business. BIOJERUSALEM is your portal to Jerusalem's thriving life science cluster. We invite you to join the numerous biotechnology, pharmaceutical and medical device companies that have already realized the advantages and enormous potential of Jerusalem. Use our services to explore the vast opportunities available to expand and grow your business. BIOJERUSALEM is an initiative of the Jerusalem Development Authority.

**10:30 – 11:30**

### **Prof. Raphael Mechoulam**

Dr. Mechoulam is a pioneer in the field of cannabis research and a discoverer of the endocannabinoid system. Dr. Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. He was among the first to complete the total synthesis of the major plant cannabinoids  $\Delta^9$ -tetrahydrocannabinol, cannabidiol, cannabigerol, and others. Dr. Mechoulam also played a key role in the isolation of the first described endocannabinoid anandamide. Prof. Mechoulam received his Masters Degree in Biochemistry from the Hebrew University in 1952 and his Ph.D. from the Weizmann Institute in 1958 where he studied under Professor F. Sondheimer. He completed his postdoctoral research at the Rockefeller Institute. Dr. Mechoulam is currently with the Institute for Drug Research at the Faculty of Medicine at the Hebrew University in Jerusalem. He is former Rector of the University and is a member of the Israel Academy of Sciences. Dr. Mechoulam has received many honours, including honorary doctorates from Spain and USA, the Israel Prize in 2000 and the European College of Neuropsychopharmacology Lifetime Achievement Award in 2006. In 2012, he received the Rothschild Prize. His research interests are in the field of the chemistry and biological activity of natural products and medicinal agents. His main contributions are in the field of the constituents of cannabis and the endogenous cannabinoids found in the brain and the periphery. He has published extensively on their pharmacological activities.

**12:30 – 14:30**

### **Jerusalem BioPark Companies**

**NovellusDX**

**CellCure Neurosciences**

**Hadasit**

The Hadassah Medical Center Hebrew University Biotechnology Park (JBP) Ein-Kerem, Jerusalem is the place to be for life science companies who want it all: strategic location, state-of-the-art facilities and a rich infrastructure. JBP is located in the heart of the Ein Kerem Hadassah campus, right next to Hadassah University Hospitals and Hebrew University's Medical School. This proximity fosters synergistic partnerships between Hadassah's institutions and the companies and professionals based in the park, all who share the goal of developing therapeutic life science technologies. JBP is the place for companies to grow and thrive, as their best and brightest collaborate to advance scientific initiatives from bench to the bedside.



## **SUNDAY 27<sup>th</sup> MAY – CONT'D**

**15:00 – 16:00**

**Teva Pharmaceuticals (includes lunch)**

**Dr. Ralph Laufer, Senior VP, Head of Discovery and Product Development**

[www.tevapharm.com](http://www.tevapharm.com)

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is a global pharmaceutical company that develops, produces, and markets generic drugs, innovative specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, Teva is one of the world's largest generic drug makers, with a product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory oncology, pain, and women's health. Teva currently employs approximately 45,000 people around the world and reached \$20.3 billion in net revenues in 2014.

**19:00**

**Dinner with Guests**

**21:30**

**Tower of David Sound and Light Show**

## **MONDAY 28<sup>th</sup> MAY**

**09:30 – 10:30**

### **Israel Innovation Authority**

**Mr. Aharon Aharon, CEO**

[www.matimop.org.il](http://www.matimop.org.il)

The Israel Innovation Authority (IAA), formerly the Office of the Chief Scientist of the Ministry of Economy (& MATIMOP), is responsible for Israel's innovation policy. It is an independent and impartial public entity that develops Israeli innovation resources, while creating and strengthening the infrastructure to support the entire knowledge industry. The IAA advises government and Parliament committees on innovation policy, monitoring and analysing dynamic changes in Israel and abroad. The IAA partners with counterpart agencies to promote Israeli technological industrial and economic innovation.

**11:30 – 12:30**

### **FutuRX**

**Dr. Einat Zisman, CEO**

[www.futurx.co.il](http://www.futurx.co.il)

At FutuRx, Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. and OrbiMed Israel Partners teamed with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines by applying a unique structure of equally balanced partnership among its three founding organizations. FutuRx envisions its role as a catalyst for drug development by bridging the gap between concept and proof-of-concept through its dedicated system and unique structure. FutuRx management, together with its founders, will establish and fully support the companies via its in-house laboratory and management facility.

## **MONDAY 28<sup>th</sup> MAY – CONT'D**

**13:00 – 16:00**

**Weizmann Institute of Science**

**Prof. Michal Shwartz – Department of Neurobiology**

**Dr. Ido Amit - Single Cell Genomics**

**Dr. Berta Strulovici - The Nancy & Stephen Grand Israel National Center for Personalized Medicine**

[www.weizmann.ac.il](http://www.weizmann.ac.il)

[www.weizmann.ac.il/immunology/AmitLab](http://www.weizmann.ac.il/immunology/AmitLab)

[www.g-incpm.weizmann.ac.il](http://www.g-incpm.weizmann.ac.il)

**Prof. Schwartz' lab** is conducting research on relationship between the immune system and the brain, under the title “contemporary neuroimmunology”. Their pioneering studies have overturned existing tenet on the relationships between the brain and the immune system, with clinical implications to age-related dementia, acute brain and spinal cord injury, Alzheimer's disease and other neurodegenerative or neurodevelopmental diseases. The group has researched the role of immune cells the central nervous system, including its repair and healthy maintenance, neurogenesis, the importance of the choroid plexus in the crosstalk between the CNS and the immune system and the therapeutic potential in Alzheimer's disease.

**The Amit lab** studies the genomic code enabling immune cells to differentiate to specific subtypes and devise a specific response to invading pathogens. Our main focus is to understand how gene regulatory networks activate this code. We develop and apply state of the art high throughput genomic tools and interdisciplinary approaches to address these critical biological and therapeutic questions. We believe that elucidating the underlying principles of the regulatory code will allow us to impact the future of personalized medicine. We are currently seeking highly motivated individuals who want to join us on this quest.

**(G-INCPM)** The Nancy & Stephen Grand Israel National Center for Personalized Medicine was Established in 2012 by the Weizmann Institute of Science, is an advanced research facility providing Israeli academic, medical, and biomedical industry researchers with access and guidance to state-of-the-art genomics, protein profiling, drug discovery and bioinformatics research platforms.

**19:00**

**Dinner with guests**

## **TUESDAY 29<sup>th</sup> MAY**

**09:00 – 10:00**

### **Yissum**

**Dr. Yaron Daniely, President & CEO**

[www.research.huji.ac.il](http://www.research.huji.ac.il)

[www.yissum.co.il](http://www.yissum.co.il)

**The Hebrew University of Jerusalem** is Israel's oldest university and its leading research university. Promoting multi-disciplinary cooperation in Israel and around the world, the University bridges the gap between academic research and its application in industry and society. The Authority for Research and Development is the main administrative department responsible for encouraging, promoting and regulating research activities at the University. **Yissum** is the technology transfer company of the Hebrew University of Jerusalem. It is responsible for marketing the inventions and know-how generated by the University's renowned researchers and students. The University's range of intellectual property includes inventions and know-how in many fields, including nanotechnology, medicine and pharmaceuticals, agriculture and nutrition, water and environmental technologies, computer science, homeland security, and more.

**10:30 – 11:30**

### **Oramed Pharmaceuticals**

**Dr. Simon Bruce, VP Medical Affairs**

[www.oramed.com](http://www.oramed.com)

Oramed Pharmaceuticals has developed an innovative technology to transform injectable treatments into oral therapies. The company's flagship product, an oral insulin capsule, has the potential to improve the lives of millions of diabetics around the world. It would allow type 2 patients to begin insulin therapy earlier without injections. Oramed's oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes. The company's POD (Protein Oral Delivery) technology is designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. The active protein is placed in a capsule with a protective coating that remains intact in the most acidic segments of the gut. An absorption enhancer helps the protein pass across the intestinal barrier.

**12:00 – 13:00**

### **Triox Nano**

**Prof. Itamar Willner, Chief Chemical Advisor**

[www.trioxnano.com](http://www.trioxnano.com)

Triox Nano provides a patented synergism of DNA machines and porous nanoparticles to create a vast field of intelligent nanoparticles. The Israel-based company is commercializing its patented platform, S.M.A.R.T. (Stimuli Multi Adjusted Responsive Technology), which synergizes two cutting-edge Nanotech fields: DNA molecular machines (DNA MMs) and mesoporous nanoparticles (MSNPs). A DNA MM tops each pore of an MSNP, acting as an "intelligent API gatekeeper." S.M.A.R.T.'s flexibility creates vast possibilities for intelligent nanoscale computerized machines able to sense combinations of environmental variables (e.g. ions, metabolites, and receptors) and unload active payloads (e.g. chemo, siRNA, or isotopes) accordingly. Triox Nano's therapeutic focus is triple-negative breast cancer, an aggressive form of breast cancer for which no targeted therapy exists. Preliminary animal models show that S.M.A.R.T. has 20-times higher efficacy and safety compared with the gold standard. Triox Nano's regulatory strategy includes orphan designation, a 505(b)(2) pathway, and pCR (pathologic complete response) accelerated approval after phase 2 to drastically reduce the funding and time required for commercialization.

## **TUESDAY 29<sup>th</sup> MAY – CONT'D**

**13:30 – 14:30**

### **Pepticom**

**Dr. Immanuel Lerner, CEO**

[www.pepticom.com](http://www.pepticom.com)

Pepticom is a unique artificial intelligence platform company with disruptive technology for peptide drug discovery. The platform requires a solved structure of the target protein to design a range of innovative peptides at atomic resolution. Using its technology, Pepticom discovered drug candidates for Diabetes, Immuno-therapy and Alzheimer's; two projects had generated peptides in animal models for Alzheimer's and vaccine adjuvants. This technology enables finding cures that are currently unreachable with existing discovery methods.

**15:00 – 16:00**

### **Gamida Cell**

[www.gamida-cell.com](http://www.gamida-cell.com)

Gamida Cell develops solutions in the fields of cell and immune therapy. The company's scientists have developed a broad platform technology called NAM to expand functional cells in culture to create cures for a wide range of conditions including blood cancers, genetic hematological diseases, bone marrow failure syndromes, genetic metabolic diseases, and refractory autoimmune diseases. Gamida Cell has a broad, worldwide patent portfolio and worldwide rights to all products. The company has developed a cost-effective and robust manufacturing process under GMP for each product and has in-house manufacturing capabilities

**19:00**

### **Dinner and Closing Briefing**